WO2003054005A3 - Bone polypeptide-1 - Google Patents

Bone polypeptide-1 Download PDF

Info

Publication number
WO2003054005A3
WO2003054005A3 PCT/IB2002/005778 IB0205778W WO03054005A3 WO 2003054005 A3 WO2003054005 A3 WO 2003054005A3 IB 0205778 W IB0205778 W IB 0205778W WO 03054005 A3 WO03054005 A3 WO 03054005A3
Authority
WO
WIPO (PCT)
Prior art keywords
bone
bone polypeptide
polypeptide
cdna
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2002/005778
Other languages
French (fr)
Other versions
WO2003054005A2 (en
Inventor
Christian Lanctot
Patrick Salois
Pierre Moffatt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phenogene Therapeutiques Inc
Original Assignee
Phenogene Therapeutiques Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phenogene Therapeutiques Inc filed Critical Phenogene Therapeutiques Inc
Priority to CA002469972A priority Critical patent/CA2469972A1/en
Priority to EP02805460A priority patent/EP1458749B1/en
Priority to AT02805460T priority patent/ATE505480T1/en
Priority to AU2002356392A priority patent/AU2002356392A1/en
Priority to US10/499,762 priority patent/US7425531B2/en
Priority to DE60239763T priority patent/DE60239763D1/en
Publication of WO2003054005A2 publication Critical patent/WO2003054005A2/en
Publication of WO2003054005A3 publication Critical patent/WO2003054005A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)

Abstract

The present invention relates to a bone polypeptide, particularly bone polypeptide-1 and nucleic acid molecules encoding the same. The present invention provides the human primary sequence of bone polypeptide-1 as well as sequences of vertebrate homologs .The invention also provides cell lines engineered to express the cDNA, antibodies to detect its translation products, and recombinant adenoviruses to deliver an expressible cDNA into a host. Bone polypeptide-1can be utilized to treat diseases affecting renal and bone functions.
PCT/IB2002/005778 2001-12-20 2002-12-20 Bone polypeptide-1 Ceased WO2003054005A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002469972A CA2469972A1 (en) 2001-12-20 2002-12-20 Bone polypeptide-1
EP02805460A EP1458749B1 (en) 2001-12-20 2002-12-20 Bone polypeptide-1
AT02805460T ATE505480T1 (en) 2001-12-20 2002-12-20 BONE POLYPEPTIDE-1
AU2002356392A AU2002356392A1 (en) 2001-12-20 2002-12-20 Bone polypeptide-1
US10/499,762 US7425531B2 (en) 2001-12-20 2002-12-20 Bone polypeptide-1
DE60239763T DE60239763D1 (en) 2001-12-20 2002-12-20 KNOCHENPOLYPEPTID-1

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34122401P 2001-12-20 2001-12-20
US60/341,224 2001-12-20

Publications (2)

Publication Number Publication Date
WO2003054005A2 WO2003054005A2 (en) 2003-07-03
WO2003054005A3 true WO2003054005A3 (en) 2003-10-23

Family

ID=23336705

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/005778 Ceased WO2003054005A2 (en) 2001-12-20 2002-12-20 Bone polypeptide-1

Country Status (7)

Country Link
US (2) US20030125258A1 (en)
EP (1) EP1458749B1 (en)
AT (1) ATE505480T1 (en)
AU (1) AU2002356392A1 (en)
CA (1) CA2469972A1 (en)
DE (1) DE60239763D1 (en)
WO (1) WO2003054005A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1634951B1 (en) * 2003-06-16 2012-05-02 Takeda Pharmaceutical Company Limited Novel protein
ES2365023T3 (en) 2004-04-21 2011-09-20 Enobia Pharma Inc. CONJUGATES OF BONE ADMINISTRATION AND METHOD OF USE OF THE SAME TO DIRECT BONE PROTEINS.
WO2005115118A2 (en) 2004-05-25 2005-12-08 Chestnut Medical Technologies, Inc. Flexible vascular occluding device
US7309589B2 (en) * 2004-08-20 2007-12-18 Vironix Llc Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16S ribosomal RNA gene and identification of bacterial species by amplicon sequencing
JP4761812B2 (en) * 2005-04-18 2011-08-31 武田薬品工業株式会社 Musclin receptor and use thereof
US7470668B2 (en) * 2005-08-24 2008-12-30 Enobia Pharma Inc. Method of use of specific natriuretic peptide receptor c ligands, transgenic non-human mammals expressing specific natriuretic peptide receptor c antagonists and cells thereof
WO2008038394A1 (en) 2006-09-30 2008-04-03 Takeda Pharmaceutical Company Limited Musclin receptor and use thereof
US9266939B2 (en) 2010-12-27 2016-02-23 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
RU2708068C2 (en) 2014-12-05 2019-12-04 Алексион Фармасьютикалз, Инк. Treating convulsions using recombinant alkaline phosphatase
CA2973883A1 (en) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
AU2016272282A1 (en) * 2015-05-29 2018-01-25 Igisu Co., Ltd. Cyclic peptide, and medicine, external preparation and cosmetic each containing said cyclic peptide
US11352612B2 (en) 2015-08-17 2022-06-07 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFICIENT POSOLOGICAL REGIMES FOR NON-SPECIFIC TISSUE ALKALINE ENZYME PHOSPHATASE REPLACEMENT HYPOPHOSPHATASE (TNSALP) THERAPY
EP3368062A4 (en) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
WO2017173413A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
EP3464573B1 (en) 2016-06-06 2026-03-04 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
US20180194824A1 (en) * 2016-12-14 2018-07-12 University Of Iowa Research Foundation Musclin peptides and methods of use thereof
KR20240158374A (en) 2017-03-31 2024-11-04 알렉시온 파마슈티칼스, 인코포레이티드 Methods for treating hypophosphatasia (hpp) in adults and adolescents
US11065009B2 (en) 2018-02-08 2021-07-20 Covidien Lp Vascular expandable devices
US11065136B2 (en) 2018-02-08 2021-07-20 Covidien Lp Vascular expandable devices
JP2021519590A (en) 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド Glycoprotein production
JP7820148B2 (en) 2018-08-10 2026-02-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド Methods of treating neurofibromatosis type 1 and related conditions using alkaline phosphatase
AU2020398898A1 (en) 2019-12-09 2022-07-21 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
US12083169B2 (en) 2021-02-12 2024-09-10 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1634951B1 (en) 2003-06-16 2012-05-02 Takeda Pharmaceutical Company Limited Novel protein
US7470668B2 (en) * 2005-08-24 2008-12-30 Enobia Pharma Inc. Method of use of specific natriuretic peptide receptor c ligands, transgenic non-human mammals expressing specific natriuretic peptide receptor c antagonists and cells thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No relevant documents disclosed *

Also Published As

Publication number Publication date
US20030125258A1 (en) 2003-07-03
AU2002356392A1 (en) 2003-07-09
CA2469972A1 (en) 2003-07-03
AU2002356392A8 (en) 2003-07-09
WO2003054005A2 (en) 2003-07-03
US7425531B2 (en) 2008-09-16
EP1458749B1 (en) 2011-04-13
ATE505480T1 (en) 2011-04-15
DE60239763D1 (en) 2011-05-26
EP1458749A2 (en) 2004-09-22
US20050143562A1 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
WO2003054005A3 (en) Bone polypeptide-1
WO2003018771A3 (en) A system for antibody expression and assembly
WO2004075861A3 (en) Recombinant adeno-associated virus production
WO2006065582A3 (en) Muteins of fibroblast growth factor 21
MXPA02002384A (en) Fibroblast growth factor like polypeptides.
WO1998014596A3 (en) Disease associated protein tyrosine phosphatases
WO2007095350A3 (en) Compositions and methods for use of pigment epithelial derived factor (pedf) peptide fragments
WO2003030821A3 (en) Albumin fusion proteins
WO2002008277A3 (en) Nucleic acids, vectors, host cells, polypeptides, and uses thereof
WO2001048209A3 (en) Genes identified as required for proliferation of e. coli
WO2003033658A3 (en) Neutrokine-alpha and neutrokine-alpha splice variant
WO2000044906A3 (en) GENES IDENTIFIED AS REQUIRED FOR PROLIFERATION IN $i(ESCHERICHIA COLI)
WO2003089569A3 (en) Use of il-19, il-22 and il-24 to treat hematopoietic disorders
WO2002102316A3 (en) Histone deacetylase and methods of use thereof
WO2003008449A8 (en) Ntb-a, a surface molecule involved in natural killer cells activity
WO1999054447A3 (en) Human nucleic acid sequences of bladder tumour tissue
WO2002050111A3 (en) Isolated laminin 10
WO1998018822A3 (en) Novel human lim proteins
WO2002008257A3 (en) Siglec (sialic acid-binding ig-related lectin) polypeptides and uses thereof
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna
WO2001085961A3 (en) Human caspase-12
UA84831C2 (en) Coagulation factor vii derivatives
MXPA04002103A (en) A caspase- 8 binding protein, its preparation and use.
WO2003057708A3 (en) Fusion proteins
SG161106A1 (en) Inhibitor proteins of a protease and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2469972

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002805460

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10499762

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2002805460

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP